EASTERN EQUINE ENCEPHALITIS VIRUS (EEEV)
LEVELS: Likely to occur: Effective control measures not fully understood; Occupational exposure risk: Non-foodborne transmission pathway(s) that are strongly associated with occupational exposure and can lead to human infection; Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Moderate: Manageable losses related to endemic (population) or chronic (individual) occurrence; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent; Not feasible: Eradication extremely unlikely
OVERVIEW
Eastern equine encephalitis virus (EEEV) is a mosquito-borne alphavirus in the family Togaviridae that can cause fatal encephalitis in pigs, particularly nursing piglets. EEEV is endemic in eastern Canada, the United States east of the Mississippi River, the Caribbean islands, and Central and South America. The virus is maintained in endemic cycles by ornithophilic mosquitoes (Culiseta melanura) and transmitted to mammals during epidemic cycles by bridge vectors including Aedes, Anopheles, and Coquillettidia species that feed on both birds and mammals. EEEV infection in pigs is not uncommon based on serosurveys, but clinical disease episodes are rare. Natural outbreaks were reported in 1972 in 3-week-old pigs and in 1991 in pigs under 2 weeks of age with 80% mortality. Nursing pigs are most severely affected, while infection in pigs 2 months of age or older is typically subclinical. Clinical signs in affected piglets include incoordination, depression, seizures, vomiting, low fever, and mortality. Survivors typically experience growth retardation. The incubation period ranges from 1 to 3 days under experimental conditions. EEEV is a significant zoonotic pathogen causing encephalitis in humans with high case fatality rates. Vaccines are available for humans and horses but not specifically licensed for swine, though vaccination may be economically justifiable during severe outbreaks or to protect valuable animals.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Likely to occur: Effective control measures not fully understood
EEEV is a documented zoonotic pathogen that causes severe encephalitis in humans. The chapter states it is a member of "alphaviruses" that "cause a variety of human and animal diseases." While the primary transmission route to humans is mosquito bite rather than food consumption, the presence of virus in tissues of acutely infected pigs during viremia creates theoretical foodborne risk. Viremia is described as "the key to the invasion of the central nervous system," indicating systemic viral distribution. However, the practical foodborne risk is likely low given the rapid disease progression, vector-dependent transmission cycle, and typical slaughter of healthy rather than clinically ill animals. The documented zoonotic capacity through natural (mosquito-mediated) transmission justifies this level.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Occupational exposure risk: Non-foodborne transmission pathway(s) that are strongly associated with occupational exposure and can lead to human infection
EEEV causes severe, often fatal encephalitis in humans with case fatality rates of approximately 30-70% and significant neurological sequelae in survivors. Human infections occur through mosquito bites during epidemic cycles when bridge vectors acquire virus from infected birds or amplifying hosts. The chapter notes that EEEV "is zoonotic and causes encephalitis in humans." While pigs are not the primary amplifying host (birds serve this role), infected pigs could theoretically contribute to local mosquito infection during viremic periods. Laboratory-acquired infections are also documented with alphaviruses. The virus's well-established zoonotic capacity warrants this classification.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity
EEEV transmission depends on mosquito vectors that cannot be fully controlled by standard biosecurity: (1) Vector-dependent transmission: Endemic cycles maintained by ornithophilic mosquitoes (Culiseta melanura); epidemic spread via Aedes, Anopheles, and Coquillettidia species that bridge between birds and mammals; (2) Environmental factors: Disease distribution reflects mosquito habitat and activity patterns rather than farm management; (3) No pig-to-pig transmission documented: The virus spreads via vector bites, not direct contact or fomites. Standard biosecurity measures (cleaning, disinfection, visitor control) cannot prevent mosquito access to outdoor or semi-outdoor housing. Indoor housing and vector control (repellents, insecticides, housing during peak feeding times) can reduce but not eliminate exposure risk in endemic areas.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
Clinical recognition in pigs is challenging due to rarity, but laboratory confirmation is established: (1) Rare clinical disease: Most infections are subclinical; clinical outbreaks are uncommon; (2) Nonspecific neurological signs: Depression, incoordination, seizures overlap with other CNS diseases; (3) Acute pigs may lack lesions: "Pigs that die in the acute phase may not have CNS lesions"; (4) Laboratory diagnosis: "Diagnosis of EEEV infection can be performed by viral isolation using CNS tissues and/or oropharyngeal and rectal swabs and tonsils in Vero cells, followed by identification by IF or RT-PCR"; (5) Serology: Variable seropositive rates in endemic areas provide population-level evidence. The main challenge is considering EEEV in the differential diagnosis, particularly given its rarity in swine compared to horses.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Moderate: Manageable losses related to endemic (population) or chronic (individual) occurrence
EEEV causes significant but sporadic losses when outbreaks occur: (1) High mortality in nursing pigs: Up to 80% mortality reported in pigs under 2 weeks of age in the 1991 outbreak; (2) Age-dependent susceptibility: "Nursing pigs are most severely affected"; "infection in pigs aged 2 months or older is inapparent"; (3) Growth retardation in survivors: "Growth is usually retarded in survivors"; (4) Rare occurrence: Clinical outbreaks are infrequent—only two natural outbreaks reported (1972 and 1991); most infections are subclinical based on seroprevalence data; (5) Geographic limitation: Disease restricted to endemic areas in eastern North America, Caribbean, and Latin America. While individual outbreak losses can be severe, the sporadic nature and geographic limitation make overall industry impact manageable.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
EEEV detection in swine does not trigger significant trade restrictions: (1) Endemic status: EEEV is endemic in eastern North America—detection does not change regional disease status; (2) Vector-dependent: Disease cannot spread through animal movements without competent vectors; (3) Primary concern is equine: Regulatory attention focuses on horses rather than swine; (4) Public health measures: Human cases trigger mosquito control efforts rather than animal trade restrictions. Detection in swine is primarily a local herd health concern rather than a trade or market issue.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
EEEV is an RNA virus (family Togaviridae, genus Alphavirus) that does not carry, acquire, or transmit antimicrobial resistance genes. The virus poses no AMR concerns.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for EEEV. The chapter states: "There is no treatment for pigs clinically affected by EEEV." Management is supportive. Given the acute nature of disease and rarity of outbreaks in swine, antimicrobial use associated with EEEV would be limited to supportive care for secondary complications, representing minimal AMR pressure.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
The chapter explicitly states: "There is no treatment for pigs clinically affected by EEEV." No specific antiviral therapy exists. Management is supportive only, and clinically affected pigs, particularly young piglets, often die or survive with neurological deficits and growth retardation.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent
Vaccines exist but are not specifically licensed for swine: "Vaccines are available for humans and horses. Vaccination may be economically justifiable in severe outbreaks or for the protection of valuable pigs." The chapter notes that "vaccination of sows provides protective maternal antibodies to piglets," demonstrating that available vaccines can protect swine. Limitations include: no swine-specific licensed product, cost-benefit considerations for commercial production, and the need for annual revaccination due to waning immunity. Prevention also relies on vector control and housing modifications.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Not feasible: Eradication extremely unlikely
EEEV eradication from the US is not possible: (1) Wild bird reservoir: Endemic cycles maintained in wild bird populations by ornithophilic mosquitoes; (2) Mosquito vectors: Multiple mosquito species serve as vectors; elimination impossible; (3) Environmental persistence: Virus maintained in bird-mosquito cycles independent of domestic animals; (4) Climate factors: Disease patterns reflect mosquito ecology, not agricultural practices; (5) Multi-host virus: Infects horses, pigs, humans, and various wildlife species. Control focuses on protecting susceptible animals through vaccination, housing modifications, and vector control rather than attempting elimination. The chapter notes no apparent increase in pig episodes despite recent climate extremes, but the virus remains endemic in its geographic range.